Last reviewed · How we verify
ultra-micronized palmitoylethanolamide
Ultra-micronized palmitoylethanolamide (um-PEA) is an endogenous lipid mediator that modulates inflammatory and neuropathic pain pathways through PPAR-α activation and mast cell stabilization.
Ultra-micronized palmitoylethanolamide (um-PEA) is an endogenous lipid mediator that modulates inflammatory and neuropathic pain pathways through PPAR-α activation and mast cell stabilization. Used for Neuropathic pain, Chronic pain conditions, Neuroinflammatory disorders.
At a glance
| Generic name | ultra-micronized palmitoylethanolamide |
|---|---|
| Also known as | um-PEA, Normast |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico |
| Drug class | Endocannabinoid-like lipid mediator / PPAR-α agonist |
| Target | PPAR-α; mast cell stabilization |
| Modality | Small molecule |
| Therapeutic area | Neurology / Pain Management / Immunology |
| Phase | FDA-approved |
Mechanism of action
Palmitoylethanolamide is an endocannabinoid-like compound that reduces neuroinflammation by activating peroxisome proliferator-activated receptor alpha (PPAR-α) and stabilizing mast cells, thereby decreasing the release of pro-inflammatory mediators. The ultra-micronized formulation enhances bioavailability and absorption compared to standard formulations. This mechanism makes it effective for neuropathic pain and inflammatory conditions.
Approved indications
- Neuropathic pain
- Chronic pain conditions
- Neuroinflammatory disorders
Common side effects
- Gastrointestinal disturbances
- Headache
- Generally well-tolerated with minimal adverse events
Key clinical trials
- Observational Metabolic Health Study
- Endocannabinoid Activity Remodulation for Psychosis Liability in Youth (NA)
- Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients (PHASE4)
- Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients (PHASE4)
- Efficacy of Ultra-micronized Palmitoylethanolamide (Um-PEA) in Geriatric Patients With Chronic Pain (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: